Mechanisms of disease: The role of heat-shock protein 90 in genitourinary malignancy

Nature Clinical Practice Urology

Volumn 3, Issue 11, 2006, Pages 590-601

  Lattouf, Jean Baptiste ^a   Srinivasan, Ramaprasad ^a   Pinto, Peter A ^a   Linehan, W Marston ^a   Neckers, Leonard ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ALANINE AMINOTRANSFERASE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CCT 018159; CISPLATIN; CYTOCHROME P450 3A5; DOCETAXEL; ELONGIN B; ELONGIN C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; GLUCOSE TRANSPORTER 1; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE; NOVOBIOCIN; PROTEIN KINASE B; RADICICOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VER 49009;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CARCINOMA; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG TUMOR LEVEL; FATIGUE; GENETIC POLYMORPHISM; HUMAN; KIDNEY CANCER; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NONHUMAN; PANCREAS DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TESTIS CANCER; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER; VOMITING; VON HIPPEL LINDAU DISEASE;

ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; SIGNAL TRANSDUCTION; UROGENITAL NEOPLASMS;

EID: 33750710409     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0604     Document Type: Review

References (81)

1. FDA (online 20 December 2005) FDA approves new treatment for advanced kidney cancer. [http://www.fda.gov/bbs/topics/NEWS/2005/NEW01282.html] (accessed 17 August 2006)
2. FDA (online 26 January 2006) FDA approves new treatment for gastrointestinal and kidney cancer. [http://www.fda.gov/bbs/topics/news/ 2006/NEW01302.html] (accessed 17 August 2006)
3. Welch WJ and Feramisco JR (1982) Purification of the major mammalian heat shock proteins. J Biol Chem 257: 14949-1459
4. Buchner J (1999) Hsp90 & Co - a holding for folding. Trends Biochem Sci 24: 136-141
5. Kimura E et al. (1993) Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 11: 891-898
6. Ciocca DR et al. (1993) Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: Prognostic implications. J Natl Cancer Inst 85: 570-574
7. Ralhan R and Kaur J (1995) Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1: 1217-1222
8. Santarosa M et al. (1997) Expression of heat shock protein 72 in renal cell carcinoma: Possible role and prognostic implications in cancer patients. Eur J Cancer 33: 873-877
9. Rocchi P et al. (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602
10. Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772
11. Wegele H et al. (2004) Hsp70 and Hsp90 - a relay team for protein folding. Rev Physiol Biochem Pharmacol 151: 1-44
12. Jolly C and Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92: 1564-1572
13. Picard D (online July 2006) Hsp90 interactors. [http://www.picard.ch/ downloads/Hsp90interactors.pdf] (accessed 17 August 2006)
14. Prodromou C and Pearl LH (2003) Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 3: 301-323
15. Hernandez MP et al. (2002) The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem 277: 38294-38304
16. Smith DF et al. (1993) Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol Cell Biol 13: 869-876
17. Panaretou B et al. (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17: 4829-4836
18. Mimnaugh EG et al. (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801
19. Xu W et al. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99: 12847-12852
20. Budillon A et al. (2005) Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets 6: 337-351
21. Uehara Y et al. (1985) Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': Identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76: 672-675
22. Whitesell L et al. (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324-8328
23. Grenert JP et al. (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272: 23843-23850
24. Mimnaugh EG et al. (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801
25. Maloney A and Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2: 3-24
26. Kelland LR et al. (1999) DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91: 1940-1949
27. Eiseman JL et al. (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimet hylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55: 21-32
28. Kamal A et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410
29. DeBoer C et al. (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23: 442-447
30. Supko JG et al. (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305-315
31. Schnur RC et al. (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38: 3806-3812
32. Schulte TW and Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279
33. Banerji U et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161
34. Goetz MP et al. (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087
35. Grem JL et al. (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-1893
36. Ramanathan RK et al. (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 3385-3391
37. Smith V et al. (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56: 126-137
38. Hollingshead M et al. (2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56: 115-125
39. Marcu MG et al. (2000) Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 92: 242-248
40. Soti C et al. (2002) A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 277: 7066-7075
41. Barril X et al. (2006) 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg Med Chem Lett 16: 2543-2548
42. Vilenchik M et al. (2004) Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11: 787-797
43. Feldman BJ and Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45
44. Grossmann ME et al. (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697
45. Visakorpi T et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406
46. Gregory CW et al. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898
47. Veldscholte J et al. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669
48. Culig Z et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478
49. Yeh S et al. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458-5463
50. Wen Y et al. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845
51. Signoretti S et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1929
52. Spiotto MT and Chung TD (2000) STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195
53. Thomas SA et al. (1996) Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 77: 367-372
54. Solit DB et al. (2002) 17-allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993
55. Nielsen TO et al. (2004) Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 64: 286-291
56. Fumo G et al. (2004) 17-allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103: 1078-1084
57. Munster PN et al. (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 7: 2228-2236
58. Ochel HJ and Gademann G (2005) Characterization of the combined cellular survival effects of benzoquinone-ansamycins and ionizing radiation. J Cancer Res Clin Oncol 131: 323-328
59. Heath EI et al. (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4: 138-141
60. Maher ER and Kaelin WG Jr (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76: 381-397
61. Ohh M and Kaelin WG Jr (2003) VHL and kidney cancer. Methods Mol Biol 222: 167-183
62. Gnarra JR et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90
63. Storkel S et al. (1997) Classification of renal cell carcinoma: Workgroup No 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989
64. Lubensky IA et al. (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155: 517-526
65. Schmidt L et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73
66. Dharmawardana PG et al. (2004) Hereditary papillary renal carcinoma type I. Curr Mol Med 4: 855-868
67. Isaacs JS et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944
68. Webb CP et al. (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60: 342-349
69. Lebret T et al. (2003) Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma. Cancer 98: 970-977
70. Cardillo MR et al. (2000) Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20: 4579-4583
71. Yamada T et al. (2000) Function of 90-kDa heat shock protein in cellular differentiation of human embryonal carcinoma cells. In Vitro Cell Dev Biol Anim 36: 139-146
72. Maruyama T et al. (1996) Heat shock induces differentiation of human embryonal carcinoma cells into trophectoderm lineages. Exp Cell Res 224: 123-127
73. Fang Y et al. (1996) Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271: 28697-28702
74. Minet E et al. (1999) Hypoxia-induced activation of HIF-1: Role of HIF-1α-Hsp90 interaction. FEBS Lett 460: 251-256
75. Sato S et al. (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97: 10832-10837
76. Stancato LF et al. (1997) The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272: 4013-4020
77. Xu W et al. (2001) Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276: 3702-3708
78. Jerome V et al. (1991) Growth factors acting via tyrosine kinase receptors induce HSP90 alpha gene expression. Growth Factors 4: 317-327
79. Bagatell R and Whitesell L (2004) Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol Cancer Ther 3: 1021-1030
80. Passarino G et al. (2003) Molecular variation of human HSP90α and HSP90β genes in Caucasians. Hum Mutat 21: 554-555
81. MacLean MJ et al. (2005) A yeast-based assay reveals a functional defect of the Q488H polymorphism in human Hsp90α. Biochem Biophys Res Comm 337: 133-137